BRNS Stock Summary and Trading Ideas (Barinthus Biotherapeutics PLC - American Depositary Shares | NASDAQ:BRNS)

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Barinthus Biotherapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol BRNS.

As of April 24, 2026, BRNS stock price was flat at $0.64 with 7,304 million shares trading.

BRNS has a beta of 3.31, meaning it tends to be more sensitive to market movements. BRNS has a correlation of 0.18 to the broad based SPY ETF.

BRNS has a market cap of $26.21 million. This is considered a Sub-Micro Cap stock.

BRNS has underperformed the market in the last year with a return of -21.3%, while the SPY ETF gained +31.9%. In the last 3 month period, BRNS fell short of the market, returning -11.0%, while SPY returned +3.8%. However, in the most recent 2 weeks BRNS has outperformed the stock market by returning +13.1%, while SPY returned +5.1%.

BRNS support price is $.58 and resistance is $.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BRNS shares will trade within this expected range on the day.